Therapy Areas: Oncology
Illumina Launches a New Genotyping Array, Forges Scientific Contribution to Three Genome Centres to Support the All of Us Research Programme
11 December 2018 - - US-based DNA sequencing and array-based technologies specialist Illumina, Inc. (NASDAQ: ILMN) has launched its new high-density genotyping array, the Infinium Global Diversity Array, the company said.

This new array was developed for and inspired by the All of Us Research Program. The All of Us Research Program is a historic effort to gather data from 1m or more people living in the United States, to accelerate human disease research and improve health. 

The All of Us Research Program is one of the country's most ambitious biomedical research efforts ever undertaken.

It aims to build a nationwide community of at least one m participants from all walks of life, including groups that have been historically underrepresented in research.

In September, the All of Us Research Program awarded funds totaling USD 28.6m to three genome centers around the country.

These centres will generate genomic data from biosamples contributed by the program's participants.

Ultimately, this information will become a critical component in the programme's precision medicine research platform, a national resource to support studies on a range of important health questions.

The All of Us Research Program is funded and led by the National Institutes of Health, part of the US Department of Health and Human Services.

Recognizing the significant impact that this project will have on the future of healthcare, Illumina is making a scientific contribution to the programme by providing the new Infinium Global Diversity Array to process up to 1m samples to the three genome centers, at no charge.

The new array will be a high-density chip that has been designed to enable achievement of the primary genotyping-based goals of the project.
Those goals are unparalleled coverage of a highly diverse cohort and the ability to return results to participants such as those indicated by the ACMG-59 Gene List and key pharmacogenomic variants.

Some of these genes are associated with potentially life-threatening health conditions, ranging from familial hypercholesterolemia, to breast and ovarian cancer. The array will become commercially available for others to use in mid-2019.

In addition to the new genotyping array, the awarded genome centres will employ Illumina's NovaSeq 6000 Sequencing Platformto conduct the whole genome sequencing for the All of Us Research Program.
Login
Username:

Password: